Cargando…

In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival

BACKGROUND: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a potentially curative treatment for patients with colorectal peritoneal metastases (CRPM). Patient selection is key to optimizing outcomes after CRS/HIPEC. The aim of this study was to determi...

Descripción completa

Detalles Bibliográficos
Autores principales: Said, Ibrahim, Ubink, Inge, Ewalds, Roos S. G., Arkesteijn, Johanna G. T., Verheul, Henk M. W., de Wilt, Johannes H. W., Dekker, Helena M., Bremers, Andreas J. A., de Reuver, Philip R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246798/
https://www.ncbi.nlm.nih.gov/pubmed/35430666
http://dx.doi.org/10.1245/s10434-022-11718-7
_version_ 1784739033716359168
author Said, Ibrahim
Ubink, Inge
Ewalds, Roos S. G.
Arkesteijn, Johanna G. T.
Verheul, Henk M. W.
de Wilt, Johannes H. W.
Dekker, Helena M.
Bremers, Andreas J. A.
de Reuver, Philip R.
author_facet Said, Ibrahim
Ubink, Inge
Ewalds, Roos S. G.
Arkesteijn, Johanna G. T.
Verheul, Henk M. W.
de Wilt, Johannes H. W.
Dekker, Helena M.
Bremers, Andreas J. A.
de Reuver, Philip R.
author_sort Said, Ibrahim
collection PubMed
description BACKGROUND: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a potentially curative treatment for patients with colorectal peritoneal metastases (CRPM). Patient selection is key to optimizing outcomes after CRS/HIPEC. The aim of this study was to determine the prognostic value of ascites diagnosed on preoperative imaging. METHODS: A prospective database of patients eligible for CRS/HIPEC between 2010 and 2020 was retrospectively analyzed. The presence of ascites, postoperative complications, overall survival (OS), disease-free survival (DFS), and completeness of cytoreduction were assessed. Univariable and multivariable logistic regression was performed to identify independent predictors for outcome. RESULTS: Of the 235 included patients, 177 (75%) underwent CRS/HIPEC while 58 (25%) were not eligible for CRS/HIPEC. In 42 of the 177 patients (24%) who underwent CRS/HIPEC, ascites was present on preoperative computed tomography (CT) imaging. Peritoneal Cancer Index (PCI) score was significantly higher in patients with preoperative ascites compared with patients without (11 [range 2–30] vs. 9 [range 0–28], respectively; p = 0.011) and complete cytoreduction was more often achieved in patients without ascites (96.3% vs. 85.7%; p = 0.007). There was no significant difference in median DFS and OS after CRS/HIPEC between patients with and without ascites {10 months (95% confidence interval [CI] 7.1–12.9) vs. 9 months (95% CI 7.2–10.8), and 25 months (95% 9.4–40.6) vs. 27 months (95% CI 22.4–31.6), respectively}. CONCLUSIONS: Ascites on preoperative imaging was not associated with worse survival in CRS/HIPEC patients with CRPM. Therefore, excluding patients from CRS/HIPEC based merely on the presence of ascites is not advisable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-022-11718-7.
format Online
Article
Text
id pubmed-9246798
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-92467982022-07-02 In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival Said, Ibrahim Ubink, Inge Ewalds, Roos S. G. Arkesteijn, Johanna G. T. Verheul, Henk M. W. de Wilt, Johannes H. W. Dekker, Helena M. Bremers, Andreas J. A. de Reuver, Philip R. Ann Surg Oncol Peritoneal Surface Malignancy BACKGROUND: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a potentially curative treatment for patients with colorectal peritoneal metastases (CRPM). Patient selection is key to optimizing outcomes after CRS/HIPEC. The aim of this study was to determine the prognostic value of ascites diagnosed on preoperative imaging. METHODS: A prospective database of patients eligible for CRS/HIPEC between 2010 and 2020 was retrospectively analyzed. The presence of ascites, postoperative complications, overall survival (OS), disease-free survival (DFS), and completeness of cytoreduction were assessed. Univariable and multivariable logistic regression was performed to identify independent predictors for outcome. RESULTS: Of the 235 included patients, 177 (75%) underwent CRS/HIPEC while 58 (25%) were not eligible for CRS/HIPEC. In 42 of the 177 patients (24%) who underwent CRS/HIPEC, ascites was present on preoperative computed tomography (CT) imaging. Peritoneal Cancer Index (PCI) score was significantly higher in patients with preoperative ascites compared with patients without (11 [range 2–30] vs. 9 [range 0–28], respectively; p = 0.011) and complete cytoreduction was more often achieved in patients without ascites (96.3% vs. 85.7%; p = 0.007). There was no significant difference in median DFS and OS after CRS/HIPEC between patients with and without ascites {10 months (95% confidence interval [CI] 7.1–12.9) vs. 9 months (95% CI 7.2–10.8), and 25 months (95% 9.4–40.6) vs. 27 months (95% CI 22.4–31.6), respectively}. CONCLUSIONS: Ascites on preoperative imaging was not associated with worse survival in CRS/HIPEC patients with CRPM. Therefore, excluding patients from CRS/HIPEC based merely on the presence of ascites is not advisable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-022-11718-7. Springer International Publishing 2022-04-16 2022 /pmc/articles/PMC9246798/ /pubmed/35430666 http://dx.doi.org/10.1245/s10434-022-11718-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Peritoneal Surface Malignancy
Said, Ibrahim
Ubink, Inge
Ewalds, Roos S. G.
Arkesteijn, Johanna G. T.
Verheul, Henk M. W.
de Wilt, Johannes H. W.
Dekker, Helena M.
Bremers, Andreas J. A.
de Reuver, Philip R.
In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival
title In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival
title_full In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival
title_fullStr In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival
title_full_unstemmed In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival
title_short In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival
title_sort in patients undergoing crs/hipec for colorectal adenocarcinoma with peritoneal metastases, presence of ascites on computed tomography imaging is not a prognostic marker for survival
topic Peritoneal Surface Malignancy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246798/
https://www.ncbi.nlm.nih.gov/pubmed/35430666
http://dx.doi.org/10.1245/s10434-022-11718-7
work_keys_str_mv AT saidibrahim inpatientsundergoingcrshipecforcolorectaladenocarcinomawithperitonealmetastasespresenceofascitesoncomputedtomographyimagingisnotaprognosticmarkerforsurvival
AT ubinkinge inpatientsundergoingcrshipecforcolorectaladenocarcinomawithperitonealmetastasespresenceofascitesoncomputedtomographyimagingisnotaprognosticmarkerforsurvival
AT ewaldsroossg inpatientsundergoingcrshipecforcolorectaladenocarcinomawithperitonealmetastasespresenceofascitesoncomputedtomographyimagingisnotaprognosticmarkerforsurvival
AT arkesteijnjohannagt inpatientsundergoingcrshipecforcolorectaladenocarcinomawithperitonealmetastasespresenceofascitesoncomputedtomographyimagingisnotaprognosticmarkerforsurvival
AT verheulhenkmw inpatientsundergoingcrshipecforcolorectaladenocarcinomawithperitonealmetastasespresenceofascitesoncomputedtomographyimagingisnotaprognosticmarkerforsurvival
AT dewiltjohanneshw inpatientsundergoingcrshipecforcolorectaladenocarcinomawithperitonealmetastasespresenceofascitesoncomputedtomographyimagingisnotaprognosticmarkerforsurvival
AT dekkerhelenam inpatientsundergoingcrshipecforcolorectaladenocarcinomawithperitonealmetastasespresenceofascitesoncomputedtomographyimagingisnotaprognosticmarkerforsurvival
AT bremersandreasja inpatientsundergoingcrshipecforcolorectaladenocarcinomawithperitonealmetastasespresenceofascitesoncomputedtomographyimagingisnotaprognosticmarkerforsurvival
AT dereuverphilipr inpatientsundergoingcrshipecforcolorectaladenocarcinomawithperitonealmetastasespresenceofascitesoncomputedtomographyimagingisnotaprognosticmarkerforsurvival